ReviewHuman vaccines & immunotherapeutics2013
The changing epidemiology of meningococcal disease in North America 1945-2010.
Review in Human vaccines & immunotherapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adults 56 years of age and older: a Phase II randomized study.Human vaccines & immunotherapeutics · 2020Trial
- Immunogenicity and Safety of Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Potential Hajj/Umrah Pilgrims Aged ≥ 56 Years: A Phase III, Open-Label Study.Infectious diseases and therapy · 2026Article
- Prevalence and Characteristics of Carriage ofOpen forum infectious diseases · 2022Article
- Invasive meningococcal disease in older adults in North America and Europe: is this the time for action? A review of the literature.BMC public health · 2022Review
- A Narrative Review of the W, X, Y, E, and NG of Meningococcal Disease: Emerging Capsular Groups, Pathotypes, and Global Control.Microorganisms · 2021Review
- Longitudinal study of meningococcal carriage rates in university entrants living in a dormitory in South Korea.PloS one · 2021Observational
- Epidemiological profile ofAccess microbiology · 2020Article
- Phenotypic characterization ofAccess microbiology · 2020Article
- Recent changes in the epidemiology of Neisseria meningitidis serogroup W across the world, current vaccination policy choices and possible future strategies.Human vaccines & immunotherapeutics · 2019Review
- Persistence of the immune response after 4CMenB vaccination, and the response to an additional booster dose in infants, children, adolescents, and young adults.Human vaccines & immunotherapeutics · 2019Review
- Concomitant administration of meningococcal vaccines with other vaccines in adolescents and adults: a review of available evidence.Human vaccines & immunotherapeutics · 2019Review
- Article
- Progress toward the global control of Neisseria meningitidis: 21st century vaccines, current guidelines, and challenges for future vaccine development.Human vaccines & immunotherapeutics · 2018Review
- Multicomponent meningococcal B vaccination (4CMenB) of adolescents and college students in the United States.Therapeutic advances in vaccines · 2017Review
- Impact and effectiveness of meningococcal vaccines: a review.Revista panamericana de salud publica = Pan American journal of public health · 2017Article
- Persistence of the immune response two years after vaccination with quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in Asian adolescents.Human vaccines & immunotherapeutics · 2016Article
- Genomic Analysis of Serogroup Y Neisseria meningitidis Isolates Reveals Extensive Similarities Between Carriage-Associated and Disease-Associated Organisms.The Journal of infectious diseases · 2016Article
- Routinely vaccinating adolescents against meningococcus: targeting transmission & disease.Expert review of vaccines · 2016Review
- A Case-Control Study on the Risk Factors for Meningococcal Disease among Children in Greece.PloS one · 2016Article
- Neisseria meningitidis and Streptococcus pneumoniae as leading causes of pediatric bacterial meningitis in nine Mexican hospitals following 3 years of active surveillance.Therapeutic advances in vaccines · 2016Article
Corrections and comments
- Commented on by
- Commented on byReply letter.2013
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The epidemiology of Invasive Meningococcal Disease (IMD) is distinct in the United States and Canada compared with other countries. This review describes the incidence, mortality and vaccination strategies relevant to IMD in these countries over the past 65 y. The incidence of IMD has remained consistently low in both countries during this period. Serogroup B and serogroup C have been the most prominent disease-causing serogroups. Notably, serogroup Y has recently become an important cause of IMD in the USA, but has not been as prominent in Canada. Periodic rises in incidence have been characterized by local outbreaks that have raised public concern, especially those caused by serogroup C in Canada, and serogroup B in the USA. Case fatality rates have remained consistent at around 10-20%, but vary by age and serogroup. Recent outbreaks have led to the introduction of vaccination programs for both outbreak control and routine immunization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.